Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

The Lead

Accelerate Drug Development with Optimized Content Management

August 29, 2014 8:30 am | by Steve Scribner, Principal Consultant – Life Sciences, EMC Information Intelligence Group | Articles | Comments

Getting a new drug from the laboratory to the pharmacy takes years of testing, applications and information sharing. One way to shorten the drug development life cycle is to optimize content management. Read more...          

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

AstraZeneca Releases Phase 4 Brilinta Data

September 2, 2014 3:35 pm | News | Comments

AstraZeneca announced the results of the Phase 4 ATLANTIC study, which indicates that the profile of Brilinta/Brilique (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients. Read more...

TOPICS:

Ipsen's Somatuline Gets Priority Review

September 2, 2014 3:16 pm | News | Comments

Ipsen N.A. announced that the FDA has accepted and granted priority review of its supplemental New Drug Application for Somatuline Depot 120mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors. Read more...      

TOPICS:

Scientists Make Diseased Cells Synthesize Their Own Drug

September 2, 2014 3:08 pm | News | Comments

In a new study that could ultimately lead to many new medicines, scientists have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy. Read more...     

TOPICS:
Advertisement

Amgen Submits MAA for Melanoma Treatment

September 2, 2014 2:59 pm | News | Comments

Amgen announced the submission of a Marketing Authorization Application to the European Medicines Agency via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. Read more...

TOPICS:

World is ‘Losing Battle Against Ebola,’ Group Says

September 2, 2014 2:53 pm | by Alexandra Olson and Sarah DiLorenzo | News | Comments

The international group Doctor Without Borders warned Tuesday that the world is losing the battle against Ebola and lamented that treatment centers in West Africa have been "reduced to places where people go to die alone" as authorities race to contain the disease. Read more...

TOPICS:

Single Animal-to-Human Transmission Event Sparked 2014 Ebola Outbreak

September 2, 2014 10:32 am | News | Comments

Scientists used advanced genomic sequencing technology to identify a single point of infection from an animal reservoir to a human in the current Ebola outbreak in West Africa. Read more...                  

TOPICS:

Bayer Extends Xarelto Investigation to 275,000 Patients

September 2, 2014 10:24 am | News | Comments

Bayer HealthCare and its development partner Janssen Research & Development LLC announced an expansion of the global clinical development program for the oral Factor Xa inhibitor rivaroxaban for the prevention of potentially deadly blood clots in patients at risk of arterial thromboembolism. Read more...

TOPICS:

Daiichi Sankyo Expands Drug Discovery Collaboration in Europe

September 2, 2014 10:12 am | News | Comments

Daiichi Sankyo Co. Ltd. announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global Program 2014, a collaborative drug discovery initiative for universities and research institutes in Europe. Read more...   

TOPICS:
Advertisement

Heart Failure Drug Cuts Deaths, Hospitalizations by 20%

September 2, 2014 9:44 am | News | Comments

A new study reports one of the biggest potential advances against heart failure in more than a decade— a first-of-a-kind, experimental drug that lowered the chances of death or hospitalization by about 20%. Read more...          

TOPICS:

FDA Fast Tracks Pfizer's C.diff Vaccine

August 29, 2014 2:00 pm | News | Comments

Pfizer Inc. has announced  that the FDA has granted Fast Track designation to the company’s investigational Clostridium difficile vaccine candidate (PF-06425090). Read more...                 

TOPICS:

Amgen Submits BLA for Cholesterol-Lowering Pill

August 29, 2014 2:00 pm | News | Comments

Amgen has announced the submission of a Biologics License Application (BLA) to the FDA for evolocumab seeking approval for the treatment of high cholesterol. Read more...                       

TOPICS:

Isis Initiates Phase 3 Study of FCS Drug

August 29, 2014 2:00 pm | News | Comments

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide. Read more...

TOPICS:

Drug-Delivery Vehicle Could Limit Spread of HIV, AIDS

August 29, 2014 2:00 pm | News | Comments

A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, according to new research. Read more...                         

TOPICS:

Synthesis Produces New Antibiotic

August 29, 2014 2:00 pm | News | Comments

A  collaboration at Rice University has led to the total synthesis of a recently discovered natural antibiotic. The laboratory recreation of a fungus-derived antibiotic, viridicatumtoxin B, may someday help bolster the fight against bacteria that evolve resistance to treatments in hospitals and clinics around the world. Read more...

TOPICS:

Amgen's Cholesterol-Lowering Drug Meets Co-Primary Endpoints

August 29, 2014 8:30 am | News | Comments

Amgen announced that the Phase 3 YUKAWA-2 study evaluating evolocumab in combination with statin therapy in Japanese patients with high cardiovascular risk and high cholesterol met its co-primary endpoints. Read more...       

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading